Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia

作者：Zhang, Ting-juan; Wang, Yu-Xin; Yang, Dong-qin; Yao, Dong-ming; Yang, Lei; Zhou, Jing-dong; Deng, Zhao-qun; Wen, Xiang-mei; Guo, Hong; Ma, Ji-chun; Lin, Jiang^*; Qian, Jun^*

来源：Clinical Laboratory, 2016, 62(1-2): 113-120.

DOI：10.7754/Clin.Lab.2015.150606

• miR-186
• expression
• prognosis
• acute myeloid leukemia

Background: MicroRNA-186 (miR-186) plays an important role in the pathogenesis of several cancers. Our study was intended to investigate the expression status and the prognostic implication of miR-186 in acute myeloid leukemia (AML). @@@ Methods: Real-time quantitative PCR was carried out in 112 de novo AML patients and 28 controls. @@@ Results: The level of miR-186 expression in AML was significantly down-regulated compared to normal controls (p < 0.001). Patients with low miR-186 expression presented significantly older age than those with high miR-186 expression (p = 0.004). MiR-186(high) patients had a significantly higher frequency of CEBPA mutation than miR-186(low) patients (20% and 4%, respectively, p = 0.022). In addition, miR-186(low) patients had a significantly lower complete remission (CR) rate (30% vs. 53%, respectively, p = 0.028) than miR-186(high) patients. Moreover, miR186(low) patients showed significantly shorter overall survival (OS) time than miR-186(high) patients in both whole AML and non-M3 patients (p = 0.023 and 0.026, respectively). Additionally, the adverse prognostic impact of miR-186 down-regulation was also shown in both whole AML and non-M3 patients without CEBPA mutation (p = 0.017 and 0.023, respectively). @@@ Conclusions: Our study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients.

• 出版日期2016
• 单位江苏大学